- Home
- CRNC vs LRMR Comparison
CRNC vs LRMR Comparison
Compare CRNC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRNC | LRMR |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.2M | 455.8M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CRNC | LRMR |
|---|---|---|
| Price | $10.43 | $3.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $10.25 | ★ $16.50 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.95 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $251,781,000.00 | N/A |
| Revenue This Year | $27.18 | N/A |
| Revenue Next Year | N/A | $1,816.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.85 | $2.26 |
| 52 Week High | $13.74 | $6.42 |
Technical Indicators
Market Signals| Indicator | CRNC | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 31.98 |
| Support Level | $9.06 | $3.10 |
| Resistance Level | $11.49 | $3.74 |
| Average True Range (ATR) | 0.94 | 0.19 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 34.47 | 3.64 |
Price Performance
Historical ComparisonAbout CRNC Cerence Inc.
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.